IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10292893" target="_blank" >RIV/00064203:_____/14:10292893 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/14:10292893

Výsledek na webu

<a href="http://dx.doi.org/10.1182/blood-2013-06-509794" target="_blank" >http://dx.doi.org/10.1182/blood-2013-06-509794</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/blood-2013-06-509794" target="_blank" >10.1182/blood-2013-06-509794</a>

Jazyk výsledku

angličtina

Název v původním jazyce

IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL

Popis výsledku v původním jazyce

Childhood BCR-ABL1-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has an unfavorable outcome and shows high frequency of IKZF1 deletions. The prognostic value of IKZF1 deletions was evaluated in 2 cohorts of BCR-ABL1-positive BCP-ALL patients, before tyrosine kinase inhibitors (pre-TKI) and after introduction of imatinib (in the European Study for Philadelphia-Acute Lymphoblastic Leukemia [EsPhALL]). In 126/191 (66%) cases an IKZF1 deletion was detected. In the pre-TKI cohort, IKZF1-deleted patients had an unfavorable outcome compared with wild-type patients (4-year disease-free survival [DFS] of 30.0 +/- 6.8% vs 57.5 +/- 9.4%; P = .01). In the EsPhALL cohort, the IKZF1 deletions were associated with an unfavorable prognosis in patients stratified in the good-risk arm based on early clinical response (4-year DFS of 51.9 +/- 8.8% for IKZF1-deleted vs 78.6 +/- 13.9% for IKZF1 wild-type; P = .03), even when treated with imatinib (4-year DFS of 55.5 +/- 9.5% for IKZF1-del

Název v anglickém jazyce

IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL

Popis výsledku anglicky

Childhood BCR-ABL1-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has an unfavorable outcome and shows high frequency of IKZF1 deletions. The prognostic value of IKZF1 deletions was evaluated in 2 cohorts of BCR-ABL1-positive BCP-ALL patients, before tyrosine kinase inhibitors (pre-TKI) and after introduction of imatinib (in the European Study for Philadelphia-Acute Lymphoblastic Leukemia [EsPhALL]). In 126/191 (66%) cases an IKZF1 deletion was detected. In the pre-TKI cohort, IKZF1-deleted patients had an unfavorable outcome compared with wild-type patients (4-year disease-free survival [DFS] of 30.0 +/- 6.8% vs 57.5 +/- 9.4%; P = .01). In the EsPhALL cohort, the IKZF1 deletions were associated with an unfavorable prognosis in patients stratified in the good-risk arm based on early clinical response (4-year DFS of 51.9 +/- 8.8% for IKZF1-deleted vs 78.6 +/- 13.9% for IKZF1 wild-type; P = .03), even when treated with imatinib (4-year DFS of 55.5 +/- 9.5% for IKZF1-del

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/GBP302%2F12%2FG101" target="_blank" >GBP302/12/G101: Molekulární mechanismy signalizace receptory leukocytů - jejich role ve zdraví a nemocích.</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood

ISSN

0006-4971

e-ISSN

—

Svazek periodika

123

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

1691-1698

Kód UT WoS článku

000335847700016

EID výsledku v databázi Scopus

—